Should I buy or sell Oncolytics Biotech stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONC shares. View ONC analyst ratings or view top-rated stocks .

What is Oncolytics Biotech's stock price target for 2024?

3 brokerages have issued 12-month target prices for Oncolytics Biotech's shares. Their ONC share price targets range from C$9.00 to C$9.00. On average, they predict the company's share price to reach C$9.00 in the next twelve months. This suggests a possible upside of 373.7% from the stock's current price. View analysts price targets for ONC or view top-rated stocks among Wall Street analysts .

How have ONC shares performed in 2023?

Oncolytics Biotech's stock was trading at C$2.22 at the beginning of 2023. Since then, ONC shares have decreased by 14.4% and is now trading at C$1.90. View the best growth stocks for 2023 here .

When is Oncolytics Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 1st 2024. View our ONC earnings forecast .

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech Inc. (TSE:ONC) issued its quarterly earnings results on Friday, November, 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.04.

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCY) , (ONCYF) (ONCYF) , Resverlogix (RVX) , Ballard Power Systems (BLDP) , ProMetic Life Sciences (PLI) , Bombardier (BDRBF) , Birchcliff Energy (BIR) , Enbridge (ENB) and First Majestic Silver (FR) .

How do I buy shares of Oncolytics Biotech?

Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

Oncolytics Biotech Stock Price, News & Analysis (TSE:ONC)

C$1.90

+0.01 (+0.53%)

(As of 12/5/2023 ET)

Compare

Today's Range: C$1.86
▼
C$1.91
50-Day Range: C$1.82
▼
C$2.99
52-Week Range: C$1.48
▼
C$4.49

Volume: 30,606 shs
Average Volume: 110,152 shs
Market Capitalization: C$139.46 million

P/E Ratio: N/A
Dividend Yield: 0.31%
Price Target: C$9.00

Stock Analysis Analyst Forecasts Chart Competitors Earnings Headlines Insider Trades

About Oncolytics Biotech Stock (TSE:ONC)

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

ONC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ONC Stock News Headlines

November 28, 2023 | americanbankingnews.com

Oncolytics Biotech (TSE:ONC) Stock Passes Below 200 Day Moving Average of $2.82

November 9, 2023 | finance.yahoo.com

Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep

December 6, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 3, 2023 | benzinga.com

Oncolytics Biotech's Earnings Outlook

November 3, 2023 | finanznachrichten.de

Oncolytics Biotech Inc.: Oncolytics Biotech Reports Third Quarter 2023 Financial Results and Operational Highlights

November 3, 2023 | finanznachrichten.de

Oncolytics Biotech Inc.: Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC

November 3, 2023 | finance.yahoo.com

Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC

November 3, 2023 | msn.com

Oncolytics Biotech GAAP EPS of -$0.14 misses by $0.06

December 6, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

November 3, 2023 | finance.yahoo.com

Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights

October 23, 2023 | marketwatch.com

Oncolytics Shares Rise 9.3% as Data Presented From Pancreatic Cancer Study

October 20, 2023 | finanznachrichten.de

USA News Group: Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research

October 20, 2023 | finanznachrichten.de

Oncolytics Biotech® Inc.: Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

September 28, 2023 | ca.finance.yahoo.com

Stocks in play: Oncolytics Biotech, Inc.

September 22, 2023 | baystreet.ca

Pioneering the Path to Cure Cancer: 2023's Biotech Innovations

September 20, 2023 | finanznachrichten.de

USA News Group: On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope

September 13, 2023 | msn.com

Oncolytics Biotech: Is The Early Data Really That Good?

August 29, 2023 | finance.yahoo.com

3 Under-$20 Stocks to Buy for Explosive Returns

August 18, 2023 | markets.businessinsider.com

JonesTrading downgrades TRACON Pharmaceuticals (TCON) to a Hold

August 14, 2023 | finanznachrichten.de

Oncolytics Biotech® Inc.: Oncolytics Biotech® Reports Second Quarter 2023 Financial Results and Operational Highlights

August 14, 2023 | msn.com

Oncolytics Biotech GAAP EPS of -C$0.12

August 14, 2023 | finance.yahoo.com

Oncolytics Biotech® Reports Second Quarter 2023 Financial Results and Operational Highlights

August 3, 2023 | markets.businessinsider.com

JonesTrading Remains a Buy on Cassava Sciences (SAVA)

July 31, 2023 | marketwatch.com

Oncolytics Biotech Stock Down 15% on Deal for Discounted Offering

July 31, 2023 | finanznachrichten.de

Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces US$15 Million Bought Deal Offering of Units

July 31, 2023 | finance.yahoo.com

Oncolytics Biotech® Announces US$15 Million Bought Deal Offering of Units

July 26, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for Gossamer Bio (GOSS)

See More Headlines

Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/03/2023
Today: 12/06/2023
Next Earnings (Estimated): 3/01/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: TSE:ONC
CUSIP: N/A
CIK: N/A
Web: www.oncolyticsbiotech.com
Phone: +1-403-6707380
Fax: N/A
Employees: 29
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: C$9.00
High Stock Price Target: C$9.00
Low Stock Price Target: C$9.00
Potential Upside/Downside: +373.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): C($0.51)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: C$-32,360,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -112.71%
Return on Assets: -49.16%

Debt

Debt-to-Equity Ratio: 1.77
Current Ratio: 4.53
Quick Ratio: 8.86

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: C$0.45 per share
Price / Cash Flow: 4.22
Book Value: C$0.40 per share
Price / Book: 4.75

Miscellaneous

Outstanding Shares: 73,400,000
Free Float: N/A
Market Cap: C$139.46 million
Optionable: Not Optionable
Beta: 1.74

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Matthew C. Coffey M.B.A.
Ph.D., President, CEO & Director
Mr. Kirk J. Look C.A.
CA, Chief Financial Officer
Mr. Andrew R. de Guttadauro (Age 56)
Global Head of Business Development & President of Oncolytics Biotech (U.S.) Inc
Comp: $634.74k
Dr. Thomas C. Heineman M.D.
Ph.D., Chief Medical Officer
Ms. Allison Hagerman P.Eng.
P.M.P., Vice President of Product Development
Jon Patton
Director of Investor Relations & Communication
Mr. John Mark Lievonen F.C.A.
FCA, LLD, Consultant

Key Competitors

View All Competitors

ONC Stock Analysis - Frequently Asked Questions

Should I buy or sell Oncolytics Biotech stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONC shares.
View ONC analyst ratings or view top-rated stocks.
What is Oncolytics Biotech's stock price target for 2024?: 3 brokerages have issued 12-month target prices for Oncolytics Biotech's shares. Their ONC share price targets range from C$9.00 to C$9.00. On average, they predict the company's share price to reach C$9.00 in the next twelve months. This suggests a possible upside of 373.7% from the stock's current price.
View analysts price targets for ONC or view top-rated stocks among Wall Street analysts.
How have ONC shares performed in 2023?: Oncolytics Biotech's stock was trading at C$2.22 at the beginning of 2023. Since then, ONC shares have decreased by 14.4% and is now trading at C$1.90.
View the best growth stocks for 2023 here.
When is Oncolytics Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, March 1st 2024.
View our ONC earnings forecast.

How were Oncolytics Biotech's earnings last quarter?: Oncolytics Biotech Inc. (TSE:ONC) issued its quarterly earnings results on Friday, November, 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.04.
What other stocks do shareholders of Oncolytics Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), (ONCYF) (ONCYF), Resverlogix (RVX), Ballard Power Systems (BLDP), ProMetic Life Sciences (PLI), Bombardier (BDRBF), Birchcliff Energy (BIR), Enbridge (ENB) and First Majestic Silver (FR).
How do I buy shares of Oncolytics Biotech?: Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:ONC) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial